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OBJECTIVE — The existence of an obese subgroup with a healthy metabolic proﬁle and low
diabetes risk has been proposed; yet long-term data are lacking. We aimed to investigate asso-
ciations between combinations of BMI categories and metabolic syndrome and risk of type 2
diabetes in middle-aged men.
RESEARCH DESIGN AND METHODS — At age 50, cardiovascular risk factors were
assessed in 1,675 participants without diabetes in the community-based Uppsala Longitudinal
Study of Adult Men (ULSAM) study. According to BMI/metabolic syndrome status, they were
categorized as normal weight (BMI 25 kg/m
2) without metabolic syndrome (National Choles-
terol Education Program criteria, n  853), normal weight with metabolic syndrome (n  60),
overweight (BMI 25–30 kg/m
2) without metabolic syndrome (n  557), overweight with met-
abolicsyndrome(n117),obese(BMI30kg/m
2)withoutmetabolicsyndrome(n28),and
obese with metabolic syndrome (n  60). We investigated the associations between BMI/
metabolic syndrome categories at baseline and diabetes incidence.
RESULTS — After 20 years, 160 participants had developed diabetes. In logistic regression
models adjusting for age, smoking, and physical activity, increased risks for diabetes were
observed in the normal weight with metabolic syndrome (odds ratio 3.28 [95% CI] 1.38–7.81;
P0.007),overweightwithoutmetabolicsyndrome(3.49[2.26–5.42];P0.001),overweight
with metabolic syndrome (7.77 [4.44–13.62]; P  0.001), obese without metabolic syndrome
(11.72 [4.88–28.16]; P  0.001), and obese with metabolic syndrome (10.06 [5.19–19.51];
P  0.001) categories compared with the normal weight without metabolic syndrome category.
CONCLUSIONS — Overweight or obese men without metabolic syndrome were at in-
creased risk for diabetes. Our data provide further evidence that overweight and obesity in the
absence of the metabolic syndrome should not be considered a harmless condition.
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H
igher BMI has consistently been as-
sociated with an increased risk for
type 2 diabetes (1,2). One reason
for the major impact of obesity on the de-
velopment of type 2 diabetes is that it of-
ten is accompanied by the metabolic
syndrome, a cluster of hyperglycemia,
dyslipidemia, and hypertension (3).
It has been proposed that the associ-
ation between BMI and the development
of type 2 diabetes is more complex than a
mere a dose-response relationship (4,5).
The existence of a metabolically healthy
but obese phenotype (MHO) has been
proposed, an obese subgroup with a
healthy metabolic proﬁle and with no in-
creased risk for adverse outcomes such as
diabetes or cardiovascular disease (4–6).
It should, however, be noted that the
MHOhypothesisisnotundisputed;itwas
recently reported that both overweight
and obese middle-aged men without the
metabolic syndrome were at increased
risk for cardiovascular events and total
mortality during 30 years of follow-up
(7).
In a recent report from the Framing-
ham Heart Study, overweight or obese in-
dividuals without the metabolic
syndrome did not portray a signiﬁcantly
increased risk for diabetes, whereas par-
ticipants with the metabolic syndrome
were at substantially higher risk for dia-
betes regardless of BMI status (8). How-
ever,inthispreviousstudy,thefollow-up
did not exceed 7 years. Thus, data on the
long-term impact of different BMI/
metabolic syndrome combinations and
the risk of diabetes are still lacking.
We hypothesized that overweight
and obesity, regardless of metabolic syn-
drome status, as well as the metabolic
syndrome, regardless of BMI status,
would be associated with long-term in-
creased risk for diabetes. We tested our
hypothesis by investigating the associa-
tions of combinations of BMI categories
and the presence or absence of the meta-
bolic syndrome with long-term risk of
type 2 diabetes using data from a cohort
studyofmiddle-agedmenfollowedfor20
years.Asasecondaryaim,weinvestigated
the association between combinations of
BMI categories and the presence or ab-
senceofinsulinresistancetofutureriskof
diabetes as some previous investigators
have deﬁned MHO as obesity in the ab-
sence of insulin resistance (4,9,10).
RESEARCH DESIGN AND
METHODS— In 1970–1973, all men
born in 1920–1924 and residing in the
countyofUppsalawereinvitedtoahealth
survey (at age 50) aimed to identify risk
factors for cardiovascular disease; 82% of
the invited men participated (n  2,322).
The cohort was reinvestigated after 10
and20yearswhenthesubjectswere60
and70yearsold,respectively.Thedesignand
selection criteria for the cohort have
been described previously (11). Partici-
pantswereexcludedforthefollowingrea-
sons: diabetes at baseline (n  124) or
unavailability of data on metabolic syn-
drome components or covariates (n 
523), leaving 1,675 men as the present
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pants had available data on insulin resis-
tance.Thebaselinecharacteristicsandthe
eventratesofdiabetesinthepresentstudy
sample were similar to those for partici-
pants who were excluded because of
missingdataatbaseline(datanotshown).
Informed written consent was obtained.
and the Uppsala University Ethics Com-
mittee approved the study.
Baseline examinations and
metabolic syndrome deﬁnition
The examination at age 50 has been de-
scribed in detail previously (11). Blood
samples for fasting concentrations were
drawn in the morning after an overnight
fast. Cholesterol and triglyceride concen-
trations in serum were assayed by enzy-
matic techniques. Fasting blood glucose
was determined by an oxidase method
and insulin by radioimmunoassay. Su-
pinesystolicanddiastolicbloodpressures
weremeasuredtwiceintherightarmafter
a10-minrest,andmeanswerecalculated.
In the present study we used a mod-
iﬁed version of the National Cholesterol
Education Program (NCEP) deﬁnition of
themetabolicsyndrome(3)(Table1).Be-
cause waist circumference was only mea-
sured in a subsample of the participants
(n480),theNCEPdeﬁnitionwasmod-
iﬁed by using a BMI cut point instead of
the NCEP waist circumference criterion
(102 cm). In the subsample with data
on waist circumference, a waist circum-
ference of 102 cm corresponded to a BMI
of 29.4 kg/m
2 in a linear regression anal-
ysis (regression equation: BMI [weight in
kilograms divided by the square of height
in meters]  0.298  waist circumfer-
ence [centimeters]  1.027). This BMI
cutpointissimilartoBMIcutpointsused
in previous modiﬁed NCEP deﬁnitions of
the metabolic syndrome (12) BMI did not
differ between this subsample (25.2 
3.1kg/m
2,meanSD)andtherestofthe
cohort (25.0  3.3 kg/m
2; P  0.32).
We used the homeostasis model
(HOMA) [fasting glucose  fasting insu-
lin]/22.5) (13) and deﬁned insulin resis-
tance(IR)asHOMA-IRinthetopquartile
of the distribution in participants without
diabetes (3.43). Leisure time physical
activity was estimated using a question-
nairecontainingfourphysicalactivitycat-
egories:sedentary,moderate,regular,and
athletic (11).
By deﬁning normal weight as BMI
25kg/m
2,overweightasBMI25–30kg/
m
2, and obesity as BMI 30 kg/m
2,w e
could categorize the participants as nor-
mal weight without metabolic syndrome
(n  853), normal weight with metabolic
syndrome (n  60), overweight without
metabolic syndrome (n  557), over-
weight with metabolic syndrome (n 
117), obese without metabolic syndrome
(MHO,n28),andobesewithmetabolic
syndrome (n  60). In secondary analy-
ses, we also categorized participants ac-
cording to BMI/insulin resistance
categories:normalweightwithoutinsulin
resistance (n  652), normal weight with
insulin resistance (n  103), overweight
without insulin resistance (n  389),
overweight with insulin resistance (n 
172), obese without insulin resistance
(n  21), and obese with insulin resis-
tance (n  48).
End point deﬁnitions
Diabeteswasdeﬁnedaccordingtocurrent
World Health Organization criteria using
fasting concentrations of glucose (fasting
blood glucose 6.1 mmol/l at the base-
lineinvestigationand10-yearreinvestiga-
tion,whichcorrespondstofastingplasma
glucose 7.0 mmol/l) or fasting plasma
glucose 7.0 mmol/l at the 20-year rein-
vestigation) or the use of antidiabetes
medication at any investigation (14). Of
the present study sample, 1,364 partici-
pants attended the 10-year reinvestiga-
tion and 967 participants attended the
20-year reinvestigation. In those who did
not attend the reinvestigations, the Swed-
Table 1—Modiﬁed NCEP Adult Treatment
Panel III metabolic syndrome deﬁnition used
in the present study
Metabolic syndrome present if 3o ft h e
following criteria are fulﬁlled:
● Fasting blood glucose 5.6 mmol/l
(100 mg/dl)*
● Blood pressure 130/85 mmHg or
treatment
● Triglycerides 1.7 mmol/l (150 mg/dl)
● HDL cholesterol 1.04 mmol/l (40
mg/dl)
● BMI 29.4 kg/m
2
*Corresponds to plasma glucose 6.1 mmol/l (110
mg/dl) (14).
Table 2—Cardiovascular risk factors in different BMI/metabolic syndrome categories
Normal weight Overweight Obese
Without MetS With MetS Without MetS With MetS Without MetS With MetS
n 853 60 557 117 28 60
Age (years) 49.6  0.6 49.6  0.5 49.6  0.6 49.5  0.6 49.7  0.4 49.7  0.6
BMI (kg/m
2) 22.6  1.6 23.3  1.3 26.7  1.3 27.5  1.4 32.2  2.2 32.9  2.7
Systolic blood pressure (mmHg) 129  16 135  17 134  17 142  18 139  17 148  21
Diastolic blood pressure (mmHg) 80  10 86  98 4  10 89  10 90  12 95  12
Fasting blood glucose (mmol/l) 4.8  0.5 5.1  0.6 4.9  0.5 5.2  0.5 4.9  0.4 5.2  0.5
Fasting blood insulin (mU/l) 10.5  5.2 12.9  4.8 13.5  6.5 16.4  10.0 16.1  4.8 24.5  12.5
Serum HDL cholesterol (mmol/l) 1.5  0.4 1.0  0.2 1.4  0.3 1.0  0.3 1.4  0.4 1.2  0.3
Serum triglycerides (mmol/l) 1.6  0.7 2.9  3.0 1.9  0.8 2.9  1.4 1.5  0.4 3.1  2.4
HOMA index (mU/l   mmol/l) 2.3  1.2 3.0  1.2 2.9  1.5 3.9  2.5 3.5  1.1 5.7  2.9
Current smoking 463 (54) 42 (70) 253 (45) 66 (56) 9 (32) 33 (55)
Hypertension 273 (32) 24 (40) 259 (46) 79 (68) 17 (61) 46 (77)
Hypertension treatment 21 (3) 1 (2) 20 (4) 12 (10) 3 (11) 9 (15)
Dyslipidemia* 366 (43) 58 (97) 331 (59) 108 (92) 12 (43) 46 (77)
Lipid-lowering treatment 6 (1) 0 (0) 11 (2) 2 (2) 0 (0) 0 (0)
DataaremeansSDorn(%).Normalweight,BMI25kg/m
2;overweight,BMI25–30kg/m
2;obese,BMI30kg/m
2.MetS,metabolicsyndrome.*Dyslipidemia:
total cholesterol–to–HDL cholesterol ratio 5.0 or lipid-lowering treatment.
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was used to identify additional partici-
pants who developed diabetes during the
20-year follow-up (ICD-9 code 250 or
ICD-10 codes E10–E14).
Statistical analysis
We investigated the associations of base-
line BMI/metabolic syndrome status with
the incidence of diabetes using crude and
multivariable logistic regression. These
multivariable models were adjusted for
ageatbaseline(continuous),smokingsta-
tus (dichotomous), and level of physical
activity (ordinal). In addition, the associ-
ation between BMI/insulin resistance cat-
egories and the incidence of diabetes was
investigated in a similar manner.
To elucidate whether participants
with impaired fasting glucose at baseline
were driving the associations, we per-
formed secondary analyses in which par-
ticipants with impaired fasting glucose at
baseline were excluded (fasting blood
glucose 5.6–6.1 mmol/l, n  134).
P  0.05 from two-sided tests was
considered statistically signiﬁcant. The
statistical software package Stata 10.0
(StataCorp, College Station, TX) was
used.
RESULTS— Baseline characteristics
forthedifferentBMI/metabolicsyndrome
categories are shown in Table 2.
BMI/metabolic syndrome categories
and type 2 diabetes incidence
Duringthe20-yearfollow-up,160partic-
ipantshaddevelopedtype2diabetes.The
risk of diabetes was higher in the over-
weight and obesity categories and with
prevalent metabolic syndrome compared
with that for normal-weight individuals
without the metabolic syndrome in both
crude and multivariable models with ad-
justment for age at baseline, smoking sta-
tus,andphysicalactivity(Table3).Obese
participants, regardless of metabolic syn-
drome status, had a 10-fold increased
risk for diabetes compared with normal-
weight individuals without the metabolic
syndrome. Interestingly, the associations
were similar when participants with im-
pairedfastingglucoseatbaselinewereex-
cluded (Table 3).
BMI/insulin resistance categories
and type 2 diabetes incidence
The risk of diabetes during follow-up was
higher in the overweight and obesity cat-
egories and with prevalent insulin resis-
tance compared with that in normal-
weight individuals without insulin
resistance, both in crude and multivari-
able models (Table 4). The obese partici-
pants with insulin resistance were at
highest risk for diabetes at the investiga-
tionafter20yearscomparedwiththenor-
mal-weight individuals without insulin
resistance (Table 4); however the obese
participants without insulin resistance
also had a 11-fold increased diabetes
risk.Moreover,theassociationsweresim-
ilar when participants with impaired fast-
ing glucose at baseline were excluded
(Table 4).
CONCLUSIONS
Principal ﬁndings
In the present study, middle-aged men
with metabolic syndrome or insulin resis-
tance had an increased risk of type 2 dia-
betes, regardless of BMI status during 20
years of follow-up, compared with nor-
mal-weight men without metabolic syn-
drome or insulin resistance. The highest
risk estimate was seen in obese partici-
pants with insulin resistance. In contrast
topreviousstudies,overweightandobese
men without metabolic syndrome or
without insulin resistance had a markedly
increased diabetes risk. Thus, our data pro-
vide further evidence that opposes the no-
tion of overweight and obesity without
metabolicderangementsasharmlesscondi-
tions. Interestingly, the associations be-
tween BMI/metabolic syndrome categories,
BMI/insulin resistance categories, and dia-
betes incidence were independent of the
level of physical activity.
Comparisons with the literature
Although numerous studies have re-
ported the separate associations between
BMI, metabolic syndrome, insulin resis-
tance, and the risk for type 2 diabetes
(1,2,15), we are aware of only one study
thathasinvestigatedassociationsbetween
BMI/metabolic syndrome categories,
BMI/insulin resistance categories, and di-
abetes risk (8). In the previous study by
Meigs et al. (8), all participants with met-
abolic syndrome or insulin resistance
were at higher risk for diabetes regardless
of BMI status, whereas overweight/obese
individuals without the metabolic syn-
drome were at no increased risk. More-
over, obese participants without insulin
resistance were at a threefold higher risk
for diabetes relative to normal-weight
participants without insulin resistance,
whereas overweight individuals without
insulin resistance were at no increased
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may explain the partly conﬂicting results
between the present and this prior study:
The baseline of the present study was
20 years earlier than that for the study
byMeigsetal.(8).Ourstudysamplecon-
sisted of men only with a very narrow age
span, and the percentage of overweight
and obese participants was substantially
lower compared with that in the previous
study. Moreover, our study had a longer
follow-up and a somewhat different ap-
proach of identifying diabetes case sub-
jects and control subjects during
follow-up that may explain the higher
event rates in the present study.
Clinical implications
Given the favorable metabolic proﬁle of
the MHO individuals, the beneﬁts of
weight loss in this subgroup has been
questioned (5,14,16), and some small
scale intervention studies have suggested
that weight loss in this group may lead to
aworsenedriskproﬁle(17,18).However,
based on our observational data, over-
weight or obese persons without the met-
abolic syndrome or insulin resistance
should be considered to have a substan-
tially higher risk for diabetes compared
with normal-weight individuals without
themetabolicsyndrome.Theinﬂuenceof
weight loss on risk in such individuals
needs to be determined in intervention
studies with predeﬁned metabolic syn-
drome/insulin resistance subgroups and
hard end points. Until such studies are
available, our data oppose the concept
that individuals who are overweight/
obese without the metabolic syndrome
should not be offered weight loss
interventions.
Strength and limitations of the study
The major strength of the present study is
the long follow-up period in a well-
characterized population-based sample.
The major limitation is that the study was
performed in middle-aged men of North-
ern European ethnicity, limiting the gen-
eralizability to women and other age- and
ethnic groups. Another limitation is that
we used a modiﬁed version of the NCEP
criteria. Instead of waist circumference,
BMI was used to deﬁne central obesity.
The usefulness of waist circumference
was not evident in the early 1970s and
therefore was only measured in a small
proportion of the sample. However, be-
cause the results were similar when BMI/
insulin resistance categories were used, it
is not likely that the potential misclassiﬁ-
cation of participants has had a major im-
pact on our results. Moreover, our study
wasalsolimitedbythefactthattherewere
few participants in some of the BMI/
metabolic syndrome and BMI/insulin re-
sistance categories, leading to wider CIs
andconsequentlyahigheruncertaintyre-
garding the level of the risk estimate. Ac-
cordingly, no ﬁrm conclusions should be
drawn regarding a potential dose-response
relationship between the BMI/metabolic
syndrome and BMI/insulin resistance cate-
gories. Ideally, our results should be vali-
dated in study populations with larger
numbers of obese participants. Finally, for
thosewhodidnotattendthereinvestigation
we used the Swedish Hospital Discharge
Register to identify participants who devel-
oped diabetes during follow-up. Because
not all patients with diabetes are hospital-
ized, it is likely that some participants who
developed diabetes during follow-up were
incorrectly classiﬁed as not having diabetes
inouranalyses.However,anysuchmisclas-
siﬁcation would conservatively bias the risk
estimates.
In summary, the increased risk for
type 2 diabetes in overweight/obese men
without the metabolic syndrome or insu-
lin resistance in the present study pro-
vides additional evidence that opposes
the existence of a healthy obese pheno-
type based on the deﬁnition of absence of
the metabolic syndrome or insulin
resistance.
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